Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
15 oct. 2024 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts...
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
30 sept. 2024 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis,...
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
03 sept. 2024 08h30 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis,...
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
13 août 2024 08h00 HE
|
Galectin Therapeutics Inc.
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of...
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
01 août 2024 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of...
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
04 juin 2024 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL...
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
15 mai 2024 08h00 HE
|
Galectin Therapeutics Inc.
Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic...
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
13 mai 2024 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be...
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
09 avr. 2024 08h00 HE
|
Galectin Therapeutics Inc.
Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis...
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
29 mars 2024 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results...